We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CSCO benefits from AI infra demand, networking growth and fiscal 2027 revenue guidance of $74.8-$75.8B.
UNH raised its 2026 adjusted EPS outlook to at least $20.5, supported by improved margins and cost management.
CRM lifted fiscal 2027 revenue and EPS guidance, with brokerage targets indicating upside of up to 149.5%.
Wall Street has been suffering from severe volatility in November. The Dow — popularly known as the blue-chip index — is no exception. On Nov 18, the 30-stock index fell 1.11% or 561.25 points. The index is currently down 8.3% from its all-time high recorded on Aug. 5. Moreover, the index slid 5.9% after the declaration of the U.S. Congressional mid-term election.
However, we have identified three blue-chip stocks with a favorable Zacks Rank that have provided strong guidance and carry solid price upside potential in the near term. These are: Cisco Systems Inc. (CSCO - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) and Salesforce Inc. (CRM - Free Report) .
The chart below shows the price performance of our three picks year to date.
Image Source: Zacks Investment Research
Cisco Systems Inc.
Cisco’s prospects are benefiting from broad demand across networking, security and collaboration. AI infrastructure orders, integrated silicon and an end-of-support refresh opportunity support a multi-year networking cycle, while newer security products and Splunk’s recovery broaden the growth base. CSCO also retains operating leverage and continues to return cash to shareholders.
Strong Guidance
For the second quarter of fiscal 2027, CSCO expects revenues between $18 billion and $18.2 billion. Non-GAAP earnings are projected at $1.34-$1.36 per share, with a non-GAAP gross margin of 65-66% and an operating margin of 36-37%. For fiscal 2027, management projects revenues of $74.8-$75.8 billion and non-GAAP earnings of $5.47-$5.53 per share.
Solid Estimate Revisions
Cisco has an expected revenue and earnings growth rate of 18.4% and 20.3%, respectively, for the current year (ending July 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 0.8% over the last seven days. CSCO has a current dividend yield of 1.77%.
It has an expected revenue and earnings growth rate of 9.2% and 9.4%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 0.9% over the last seven days.
Robust Price Upside
The short-term average price target of brokerage firms represents an increase of 34% from the last closing price of $97.18. The brokerage target price is currently in the range of $109-$150. This indicates a maximum upside of 54.4% and no downside.
UnitedHealth Group Inc.
UnitedHealth Group’s diversified operations and disciplined pricing support its growth prospects. Optum remains a key earnings driver, aided by integrated care, AI-enabled solutions and pharmacy services. Commercial fee-based membership gains and a healthy sales pipeline provide further opportunities.
Higher Medicare Advantage payment rates and improved medical cost management support UNH’s earnings outlook. Cash generation also allows continued investment and shareholder returns. Healthcare demand also supports UNH’s core business.
Strong Guidance
UNH expects 2026 adjusted EPS to be at least $20.5 for 2026, up from the previously guided range of $19.5-$20, indicating improving margins. Net margin was expected to be around 3.6%, up from 2.7% in 2025. Operating cash flows were estimated to be around $24 billion, up from the previous guidance of greater than $18 billion.
Solid Estimate Revisions
UnitedHealth Group has an expected revenue and earnings growth rate of 0.4% and 26.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.7% over the last seven days. UNH has a current dividend yield of 2.38%.
It has an expected revenue and earnings growth rate of 3.2% and 13.4%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 0.7% over the last seven days.
Robust Price Upside
The short-term average price target of brokerage firms represents an increase of 36.1% from the last closing price of $349.91. The brokerage target price is currently in the range of $380-$531. This indicates a maximum upside of 51.7% and no downside.
Salesforce Inc.
Salesforce has been benefiting from its leading CRM franchise, recurring subscription revenues and expanding adoption of Agentforce and Data 360. Rising AI usage and deeper integration across workflows support expansion within its enterprise base.
Growing remaining performance obligations and longer contract terms provide CRM’s revenue visibility. Management expects organic growth to reaccelerate in the second half of fiscal 2027. Acquisitions and international investments broaden the platform and support CRM’s expansion.
Strong Guidance
Salesforce raised its fiscal 2027 revenue guidance to $46.10-$46.40 billion from $45.90-$46.20 billion. Non-GAAP operating margin guidance remains at 34.3%. CRM lifted its fiscal 2027 non-GAAP earnings outlook to $16.67-$16.71 per share from $14.06-$14.12. The company continues to expect operating cash flow and free cash flow growth of around 4%-5% year over year.
For the third quarter of fiscal 2027, CRM expects revenues of $11.42-$11.50 billion, implying 11-12% year-over-year growth, and non-GAAP earnings of $3.42-$3.44 per share. The company expects cRPO growth of approximately 14% year over year in constant currency.
Solid Estimate Revisions
Salesforce has an expected revenue and earnings growth rate of 11.4% and 33.6%, respectively, for the current year (ending January 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 0.8% over the last 60 days. CRM has a current dividend yield of 0.90%.
It has an expected revenue and earnings growth rate of 9.7% and -4.1%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 0.9% over the last 60 days.
Robust Price Upside
The short-term average price target of brokerage firms represents an increase of 51% from the last closing price of $190.40. The brokerage target price is currently in the range of $165-$475. This indicates a maximum upside of 149.5% and a downside of 13%.
Image: Bigstock
Buy 3 Blue-Chip Stocks Amid Solid Upside Despite Dow's Recent Debacle
Key Takeaways
Wall Street has been suffering from severe volatility in November. The Dow — popularly known as the blue-chip index — is no exception. On Nov 18, the 30-stock index fell 1.11% or 561.25 points. The index is currently down 8.3% from its all-time high recorded on Aug. 5. Moreover, the index slid 5.9% after the declaration of the U.S. Congressional mid-term election.
However, we have identified three blue-chip stocks with a favorable Zacks Rank that have provided strong guidance and carry solid price upside potential in the near term. These are: Cisco Systems Inc. (CSCO - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) and Salesforce Inc. (CRM - Free Report) .
Each of our picks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The chart below shows the price performance of our three picks year to date.
Image Source: Zacks Investment Research
Cisco Systems Inc.
Cisco’s prospects are benefiting from broad demand across networking, security and collaboration. AI infrastructure orders, integrated silicon and an end-of-support refresh opportunity support a multi-year networking cycle, while newer security products and Splunk’s recovery broaden the growth base. CSCO also retains operating leverage and continues to return cash to shareholders.
Strong Guidance
For the second quarter of fiscal 2027, CSCO expects revenues between $18 billion and $18.2 billion. Non-GAAP earnings are projected at $1.34-$1.36 per share, with a non-GAAP gross margin of 65-66% and an operating margin of 36-37%. For fiscal 2027, management projects revenues of $74.8-$75.8 billion and non-GAAP earnings of $5.47-$5.53 per share.
Solid Estimate Revisions
Cisco has an expected revenue and earnings growth rate of 18.4% and 20.3%, respectively, for the current year (ending July 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 0.8% over the last seven days. CSCO has a current dividend yield of 1.77%.
It has an expected revenue and earnings growth rate of 9.2% and 9.4%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 0.9% over the last seven days.
Robust Price Upside
The short-term average price target of brokerage firms represents an increase of 34% from the last closing price of $97.18. The brokerage target price is currently in the range of $109-$150. This indicates a maximum upside of 54.4% and no downside.
UnitedHealth Group Inc.
UnitedHealth Group’s diversified operations and disciplined pricing support its growth prospects. Optum remains a key earnings driver, aided by integrated care, AI-enabled solutions and pharmacy services. Commercial fee-based membership gains and a healthy sales pipeline provide further opportunities.
Higher Medicare Advantage payment rates and improved medical cost management support UNH’s earnings outlook. Cash generation also allows continued investment and shareholder returns. Healthcare demand also supports UNH’s core business.
Strong Guidance
UNH expects 2026 adjusted EPS to be at least $20.5 for 2026, up from the previously guided range of $19.5-$20, indicating improving margins. Net margin was expected to be around 3.6%, up from 2.7% in 2025. Operating cash flows were estimated to be around $24 billion, up from the previous guidance of greater than $18 billion.
Solid Estimate Revisions
UnitedHealth Group has an expected revenue and earnings growth rate of 0.4% and 26.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.7% over the last seven days. UNH has a current dividend yield of 2.38%.
It has an expected revenue and earnings growth rate of 3.2% and 13.4%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 0.7% over the last seven days.
Robust Price Upside
The short-term average price target of brokerage firms represents an increase of 36.1% from the last closing price of $349.91. The brokerage target price is currently in the range of $380-$531. This indicates a maximum upside of 51.7% and no downside.
Salesforce Inc.
Salesforce has been benefiting from its leading CRM franchise, recurring subscription revenues and expanding adoption of Agentforce and Data 360. Rising AI usage and deeper integration across workflows support expansion within its enterprise base.
Growing remaining performance obligations and longer contract terms provide CRM’s revenue visibility. Management expects organic growth to reaccelerate in the second half of fiscal 2027. Acquisitions and international investments broaden the platform and support CRM’s expansion.
Strong Guidance
Salesforce raised its fiscal 2027 revenue guidance to $46.10-$46.40 billion from $45.90-$46.20 billion. Non-GAAP operating margin guidance remains at 34.3%. CRM lifted its fiscal 2027 non-GAAP earnings outlook to $16.67-$16.71 per share from $14.06-$14.12. The company continues to expect operating cash flow and free cash flow growth of around 4%-5% year over year.
For the third quarter of fiscal 2027, CRM expects revenues of $11.42-$11.50 billion, implying 11-12% year-over-year growth, and non-GAAP earnings of $3.42-$3.44 per share. The company expects cRPO growth of approximately 14% year over year in constant currency.
Solid Estimate Revisions
Salesforce has an expected revenue and earnings growth rate of 11.4% and 33.6%, respectively, for the current year (ending January 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 0.8% over the last 60 days. CRM has a current dividend yield of 0.90%.
It has an expected revenue and earnings growth rate of 9.7% and -4.1%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 0.9% over the last 60 days.
Robust Price Upside
The short-term average price target of brokerage firms represents an increase of 51% from the last closing price of $190.40. The brokerage target price is currently in the range of $165-$475. This indicates a maximum upside of 149.5% and a downside of 13%.